Nan Fung Life Sciences
Mr. Bisgaard joined Nan Fung and Pivotal Life Sciences in 2017. He was previously a Senior Partner at Novo Ventures (US) Inc. since 2009. As part of Novo’s senior team, he was responsible for Novo Ventures’ overall investment and portfolio strategy as well as the ongoing development of the Novo Ventures team in the US. Prior to that, Mr. Bisgaard was with Novo A/S since 2001 in Denmark. He has both investment and board experience from a large number of private and public US life sciences companies. Prior to joining Novo A/S, Peter was with McKinsey & Co. as a general consultant and as a specialist within the Scandinavian Corporate Finance and Strategy Group. He was part of the strategic and financial advisory teams in multiple large Private Equity and Corporate M&A transactions and strategy projects across industry sectors. Mr. Bisgaard obtained an M.Sc. in Engineering in 1998 from the Technical University of Denmark and was awarded a post-graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry.
This person is not in any offices
Nan Fung Life Sciences
Nan Fung Life Sciences, part of Nan Fung Group, is a global investment platform focusing on life sciences. Leveraging on Nan Fung Group’s strong capital base and long-term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations, and investors in the life science space. Through direct investments via Pivotal bioVenture Partners funds (both in US and China) and fund investments covering full spectrum of the industry (including therapeutics, medical devices, and diagnostics) and across different development stages, Nan Fung Life Sciences has a significant presence in both US and Greater China.